OTX-101 0.09%

DRUG2 trials

Sponsors

Sun Pharmaceutical Industries Limited

Conditions

Dry Eye DiseaseKeratoconjunctivitis Sicca

Phase 2

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

CompletedNCT02254265

Sun Pharmaceutical Industries LimitedDry Eye Disease, Keratoconjunctivitis Sicca

Start: 2014-09-30End: 2015-05-31Updated: 2022-08-29

Phase 3

An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

CompletedNCT02845674

Sun Pharmaceutical Industries LimitedKeratoconjunctivitis Sicca

Start: 2016-07-29End: 2017-08-15Updated: 2021-11-19

Related Papers

Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca

Clinical ophthalmology2021-01-0115 citations